Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of ...

  • Simcere Zaiming announced that the first US patient has begun treatment in a Phase 1 trial at The Tisch Cancer Institute, assessing the safety and preliminary efficacy of SIM0500 in relapsed/refractory multiple myeloma patients.
  • SIM0500 is a humanized trispecific antibody targeting GPRC5D, BCMA, and CD3, developed with Simcere Zaiming's proprietary platform.
  • In April 2024, the FDA granted SIM0500 a Fast Track designation due to its potential in treating RRMM, emphasizing its promise as a cornerstone for future therapies.
  • BCMA and GPRC5D-targeted therapies have shown significant promise in treating RRMM and are expected to play a key role in future treatments.
Insights by Ground AI

68 Articles

Fox 4 Kansas CityFox 4 Kansas City
+66 Reposted by 66 other sources
Center

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

·Kansas City, United States
Read Full Article
World NewsWorld News
Center

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of ...

SHANGHAI, June 18, 2025 /PRNewswire/ -

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 70% of the sources are Center
70% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Fox 4 Kansas City broke the news in Kansas City, United States on Wednesday, June 18, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

New York City icon

New York City

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal